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Study objective: In order to reduce the risk of vaginal recurrence, we have chosen total laparoscopic
modiﬁed radical hysterectomy instead of extrafascial hysterectomy in the treatment of endometrial
cancer. The aim of this study was to assess the safety of this method.
Design: Retrospective study of gynecological patients.
Setting: Yokohama City University Medical Center, Yokohama, Japan.
Patients: Forty-nine patients who underwent total laparoscopic modiﬁed radical hysterectomy for the
treatment of endometrial cancer at our hospital between December 2011 and September 2015.
Interventions: Total laparoscopic modiﬁed radical hysterectomy þ bilateral salpingo-oophorectomy
(n ¼ 20), total laparoscopic modiﬁed radical hysterectomy þ bilateral salpingo-oophorectomy þ pelvic
lymphadenectomy (n ¼ 18), or total laparoscopic modiﬁed radical hysterectomy þ bilateral salpingo-
oophorectomy þ pelvic and para-aortic lymphadenectomy (n ¼ 11).
Measurements and Main Results: The surgical outcomes were analyzed and compared to previous re-
ports. The median operative time was 204 minutes (range, 99e504 minutes) and the median intra-
operative blood loss was 150 mL (range, 0e680 mL). No patients needed a blood transfusion, conversion
to laparotomy, or reoperation. Intra- and postoperative complications were observed in three patients
and nine patients, respectively. The amount of blood loss and the incidence of complications in our study
were almost identical to previous reports of laparoscopic hysterectomy. The operative time in our study
was equivalent to previous reports of total laparoscopic modiﬁed radical hysterectomy.
Conclusion: Total laparoscopic modiﬁed radical hysterectomy is safe and feasible for the treatment of
early stage endometrial cancer. This procedure can be an alternative to total laparoscopic hysterectomy,
especially when the uterus must be removed completely.
Copyright © 2016, The Asia-Paciﬁc Association for Gynecologic Endoscopy and Minimally Invasive
Therapy. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Endometrial cancer is the most common gynecological malig-
nant neoplasm, and its standard treatment is surgical removal of
the uterus. Total abdominal hysterectomy and bilateral salpingo-
oophorectomy with or without bilateral pelvic/para-aortics of interest relevant to this
y, Yokohama City University
ohama City, Kanagawa 232-
itagawa).
forGynecologic EndoscopyandMinim
enses/by-nc-nd/4.0/).lymphadenectomy has been the standard surgery for early stage
endometrial cancer. However, recent advances in laparoscopic
surgery have enabled it to be utilized for the treatment of early
stage endometrial cancer as a less invasive surgical option than
laparotomy. Most previous studies that compared laparoscopic
surgery to laparotomy showed a comparable or signiﬁcantly lower
incidence of treatment-related morbidity, a shorter hospital stay,
less blood loss, less pain, and a faster recovery with the laparo-
scopic approach.1 For this reason, we have also adopted laparo-
scopic surgery for the treatment of early stage endometrial cancer.
While extrafascial hysterectomy is usually recommended to
remove the uterus thoroughly, we have chosen total laparoscopic
modiﬁed radical hysterectomy (TLmRH; equivalent to Piver-ally InvasiveTherapy. PublishedbyElsevier TaiwanLLC. This is anopenaccess article under
M. Kitagawa et al. / Gynecology and Minimally Invasive Therapy 6 (2017) 6e11 7Rutledge class II hysterectomy) as a highly effective procedure to
reduce the risk of vaginal recurrence after surgery. We included the
operated cases with or without lymphadenectomy in order to
investigate the feasibility of these procedures comprehensively.
Aim
The aim of this study was to assess the safety of TLmRH, because
very few studies describing this technique have been reported thus
far.
Materials and Methods
We retrospectively reviewed the operated cases with endo-
metrial cancer at the Department of Gynecology, Yokohama City
University Medical Center, Yokohama, Japan between December
2011 and September 2015. General consent was obtained from all
patients preoperatively, and the Yokohama City University Med-
ical Center Institutional Ethics Committee approved this study.
Preoperative histological diagnosis was made via uterine cavityTable 1
Characteristics of the patients and surgical results.
All
(n ¼ 49)
Age (y) 57.0 (39e77)
BMI (kg/m2) 23.7 (17.7e39.4)
No. of nulliparous 13 (26.5)
No. of patients with any abdominal surgical history 12 (24.5)
Histological diagnosis (postoperative)
G1 33
G2 10
G3 3
Others 3
FIGO staging 2008 (postoperative)
1A 44
1B 2
2 1
3C1 2
Operative time (min) 204 (99e504)
Estimated blood loss (mL) 150 (0e680)
No. of intraoperative transfusions 0
Weight of uterus (g) 140 (85e375)
Length of cervical cuff (mm) 20.0 (10.0e27.5)
Time to make cervical cuff (min) 15.0 (3e30)
No. of dissected pelvic lymph nodes 29 (7e56)
No. of dissected para-aortic lymph nodes 37 (14e57)
Time to remove all drains (d) 3 (2e10)
Postoperative Hb value (g/dL) 10.4 (8.4e11.8)
Postoperative CRP value (mg/dL) 1.609 (0.131e10.577)
Time to walk (d) 1 (1e2)
Time to passage of ﬂatus (d) 1 (0e3)
Time to hospital stay after surgery (d) 6 (3e14)
Complications
Overall (No. of patients) 10 (20.4)
Intraoperative (No. of patients) 3 (6.1)
Bladder injury 1 (2.0)
Ureter injury 1 (2.0)
Nerve injury 1 (2.0)
Postoperative (No. of patients) 9 (18.4)
Ureterevagina ﬁstula 1 (2.0)
Urinary dysfunction requiring intervention 2 (4.1)
Neurological disorder requiring intervention 1 (2.0)
Lymphedema requiring intervention 1 (2.0)
Pelvic infection requiring intervention 1 (2.0)
Chylous ascites 1 (2.0)
Atelectasis 1 (2.0)
Vein thrombosis 1 (2.0)
Data are expressed as median (range) or n (%).
BMI ¼ body mass index; PALA ¼ para-aortic lymphadenectomy, PLA ¼ pelvic lymphadecurettage. The extent of muscle invasion was based on preoper-
ative examination using enhanced magnetic resonance imaging.
Metastases were evaluated with computed tomography (CT) scan.
TLmRH þ bilateral salpingo-oophorectomy (BSO) þ pelvic lym-
phadenectomy (PLA) þ para-aortic lymphadenectomy (PALA) was
undertaken fundamentally for the patients with endometrial
cancer. It has been reported that para-aortic lymph node
metastasis was found to be 10e17% in the endometrial cancer
when muscle invasion was > 50%.2e4 It has also been reported
that PALA is not necessary when cytological examination is
negative and pelvic lymph node metastasis is not found by pelvic
lymphadenectomy.5 Based on these observations, PALA was
excluded and TLmRH þ BSO þ PLA was undertaken for patients
with Grade 1 endometrioid cancer when superﬁcial muscle in-
vasion was suspected to be < 50%. Because it has been reported
that lymph node metastasis is seen in only 1e2% of endometrial
cancer patients when muscle invasion is not found,6,7 lympha-
denectomy was excluded and TLmRH þ BSO was undertaken for
patients with Grade 1 endometrioid cancer with no obvious
muscle invasion.Breakdown of surgical procedure
TLmRH TLmRHþPLA TLmRHþPLAþPALA
(n ¼ 20) (n ¼ 18) (n ¼ 11)
56.5 (39e73) 55.0 (46e70) 61.0 (46e77)
23.8 (17.7e39.4) 22.9 (18.3e32.9) 23.9 (18.1e30.8)
6 (30.0) 3 (16.7) 4 (36.4)
7 (35.0) 4 (22.2) 1 (9.1)
18 13 2
2 5 3
0 0 3
0 0 3
20 16 8
0 1 1
0 0 1
0 1 1
143 (99e211) 214.5 (165e274) 435 (328e504)
100 (0e325) 200 (0e680) 200 (50e520)
0 0 0
155 (85e325) 145 (85e375) 100 (85e180)
20.5 (13.5e27.5) 19.5 (10e25) 19.0 (15e25)
15.0 (3e30) 12.5 (8e21) 18.0 (12e26)
d 28 (15e47) 33 (7e56)
d d 37 (14e57)
2 (2e7) 3 (2e10) 4 (2e7)
10.8 (8.4e11.8) 10.3 (8.7e11.3) 10.8 (8.9e11.4)
1.092 (0.194e2.414) 1.675 (0.131e10.577) 3.837 (1.686e7.117)
1 (1e2) 1 (1e2) 1 (1e2)
1 (1e2) 1 (1e3) 1 (0e1)
6 (3e9) 6 (4e14) 6 (5e9)
2 (10.0) 7 (38.9) 1 (9.1)
1 (5.0) 1 (5.6) 1 (9.1)
1 (5.0) 0 0
0 0 1 (9.1)
0 1 (5.6) 0
1 (5.0) 7 (38.9) 1 (9.1)
0 1 (5.6) 0
1 (5.0) 1 (5.6) 0
0 1 (5.6) 0
0 1 (5.6) 0
0 1 (5.6) 0
0 0 1 (9.1)
0 1 (5.6) 0
0 1 (5.6) 0
nectomy; TLmRH ¼ total laparoscopic modiﬁed radical hysterectomy.
Table 2
Comparison with the previous reports of laparoscopic hysterectomy.
Study n Surgical procedure (%) Operative
time (min)
Blood loss (mL) Hospital stay
after surgery (d)
Complications (%) Transfusion (%) Conversion to
laparotomy (%)
Reoperation (%) Death (%)
Our study 49 TLmRH 40.8 204 (99e504) 150 (0e680) 6 (3e14) Intraoperative 6.1 0 0 0 0
TLmRHþPLA 36.7 Bladder 2.0, ureter 2.0, nerve 2.0
TLmRHþPLAþ
PALA 22.4
Postoperative 18.4
Urinary ﬁstula 2.0, urinary
dysfunction 4.1, neurological
disorder 2.0, lymphedema 2.0,
pelvic infection 2.0, chylous ascites
2.0, atelectasis 2.0, pulmonary
embolism 2.0
Walker et al8
(LAP2 study)
1630 TLH/LAVH/RH 1.4 204 [160e252] NR 3 [2e4] Intraoperative 10 9 25.8 3 <1
TLH/LAVH/RHþ
PLA 6.8
Bladder 1, ureter 1, intestinal 2,
artery 2, vein 3, others 2
TLH/LAVH/RHþPLA
þPALA 91.5
Postoperative 14
Urinary tract infection 2, fever 3,
pelvic cellulitis 1, abscess 1,
venous thrombophebitis 1,
pulmonary embolus 1, bowel
obstruction 1, ileus 4, pneumonia 1,
wound infection 3, urinary
tract ﬁstula 1, bowel ﬁsula 1,
congestive heart disease 1,
arrhythmia 1
Kyrgiou et al9 99 LH 54.5 105 [60e150] NR 4 (2e35) Overall 21 4 27 NR NR
LHþPLA 45.5 Ileus 2, deep venous thrombosis 2,
pulmonary embolism 1, minor
wound dehiscensce 10, other
signiﬁcant morbidity 9
Boosz et al10 107 TLH 28.0 190.6 ± 83.2 NR NR Intraoperative 5.6 NR NR 0.9 NR
TLHþPLA 36.4 Bladder 2.8, ureter 0.9, intestinal 0.9,
vagina 0.9
TLHþPLAþ
PALA 35.5
Postoperative 10.3
No detailed data
Farthing et al11 191 TLH 96.9 75 (25e300) 100 (5e2000) 2 (1e13) Intraoperative 4.19 1.57 1.04 NR 0
TLHþPLA 3.1 Visceral 1.57, vagina 1.04, vascular
0.52%, pulmonary 1.04
Postoperative 6.80
Wound infection 1.04, cardiac
causes 0.52, any bleeding 2.61,
pulmonary 1.57, visceral 1.04,
metabolic 0.52
Wright et al12 1027 TLH/LAVH 44.2 NR NR NR Overall 9.8 3.2 NR 0.8 0.2
TLH/LAVHþ
PLA 55.8
Intraoperative 4.0
Bladder 1.0, ureter 0.7, intestinal 0.5,
vascular 0.1, others 3.1
Postoperative
Wound complication 1.5, abscess 0.3,
bowel obstruction 1.0, venous
thromboembolism 0.4, cardiopulmonary
arrest 0.1, respiratory failure 3.2, renal
failure 1.2, stroke 0.2, bacteremia 0.3,
shock 0.7, pneumonia 0.3
M
.K
itagaw
a
et
al./
G
ynecology
and
M
inim
ally
Invasive
Therapy
6
(2017)
6
e
11
8
K
u
op
p
al
a
et
al
1
3
40
LH
10
14
5
±
32
17
1
±
14
5
2.
7
±
1.
1
In
tr
ao
pe
ra
ti
ve
0
2.
5
2.
5
N
R
N
R
LH
þP
LA
87
.5
Po
st
op
er
at
iv
e
37
.5
U
ro
se
p
si
s
2.
5,
lo
w
er
u
ri
n
ar
y
tr
ac
t
2.
5,
va
gi
n
al
cu
ff
el
lu
lit
is
10
,p
or
t-
si
te
w
ou
n
d
2.
5,
ly
m
p
h
ed
em
a
12
.5
.P
el
vi
c
ly
m
p
h
cy
st
2.
5,
p
or
t-
si
te
h
er
n
ia
2.
5,
ile
u
s
2.
5
M
ou
ri
ts
et
al
1
18
5
TL
H
10
0
11
5
(3
5e
26
7)
10
0
(1
0e
15
00
)
2
(1
e
25
)
O
ve
ra
ll:
m
aj
or
14
.6
,m
in
or
13
.0
3.
2
10
.8
N
R
1.
6
In
tr
ao
pe
ra
ti
ve
:
m
aj
or
2.
7,
m
in
or
8.
1
B
ow
el
2.
2,
u
re
te
r
1.
1,
bl
ad
d
er
1.
1,
h
em
or
rh
ag
e
3.
2
Po
st
op
er
at
iv
e:
m
aj
or
11
.9
,m
in
or
9.
7
In
fe
ct
io
n
38
.0
 C
2.
2,
h
em
at
om
a
0.
5,
w
ou
n
d
d
eh
is
ce
n
ce
1.
1,
w
ou
n
d
in
fe
ct
io
n
1.
6,
ile
u
s
1.
6,
u
ri
n
ar
y
tr
ac
t
in
fe
ct
io
n
7.
0,
u
ri
n
ar
y
re
te
n
ti
on
2.
2
D
at
a
ar
e
ex
p
re
ss
ed
as
m
ed
ia
n
(r
an
ge
),
m
ed
ia
n
[i
n
te
rq
u
ar
ti
le
ra
n
ge
],
or
m
ea
n
±
st
an
d
ar
d
d
ev
ia
ti
on
.
LA
V
H
¼
la
p
ar
os
co
p
ic
as
si
st
ed
va
gi
n
al
h
ys
te
re
ct
om
y;
LH
¼
la
p
ar
os
co
p
ic
h
ys
te
re
ct
om
y
(d
et
ai
ls
u
n
kn
ow
n
);
N
R
¼
n
ot
re
p
or
te
d
;P
A
LA
¼
p
ar
a-
ao
rt
ic
ly
m
p
h
ad
en
ec
to
m
y;
PL
A
¼
p
el
vi
c
ly
m
p
h
ad
en
ec
to
m
y;
R
H
¼
ro
bo
ti
c
h
ys
te
re
ct
om
y;
TL
H
¼
to
ta
l
la
p
ar
os
co
p
ic
h
ys
te
re
ct
om
y;
TL
m
R
H
¼
to
ta
l
la
p
ar
os
co
p
ic
m
od
iﬁ
ed
ra
d
ic
al
h
ys
te
re
ct
om
y.
M. Kitagawa et al. / Gynecology and Minimally Invasive Therapy 6 (2017) 6e11 9In cases where PALA was performed, this procedure was un-
dertaken through the retroperitoneal cavity, followed by TLmRH
and PLA. When PLA and/or PALA was excluded, we diagnosed the
stage of patients clinically using preoperative CT scan.
The surgical procedure for TLmRH, equivalent to PivereRutledge
class II hysterectomy, was as follows: patients were under endo-
tracheal general anesthesia in a modiﬁed dorso-lithotomy position.
To prevent the scattering of cancer cells to the vagina, a cervical cuff
was made to cover the external os of the uterus transvaginally prior
to the laparoscopic surgery. We used a ﬁve-port technique without
intrauterine manipulation. The initial 12-mm umbilical port was
inserted and the abdomen was insufﬂated with carbon dioxide
(10 mmHg). Three additional 5-mm trocars were inserted in the
right, left, and medial part of the lower abdomen at the level of the
anterior superior iliac spine. Another 5 mm trocar was inserted
under the left costal arch to retract the uteruswith grasping forceps.
After collecting peritoneal washings for cytologic examination, the
bilateral tubes were coagulated with bipolar forceps to prevent
scattering of cancer cells to the peritoneal cavity. After opening the
vesicouterine peritoneum, the round ligament was cut with an
ENSEAL tissue sealer (Ethicon Endo-Surgery, Cincinnati, OH, USA).
The uterine arteries and the ureters were identiﬁed and the uterine
arteries were ligated and cut. The vesicouterine, infundibulopelvic,
and uterosacral ligaments were transected. The paracolpium was
ligated and resected, then circumferential colpotomy was per-
formed on the rim of the Vagi-pipe (Hakko, Chikuma, Japan). The
uterus and adnexa were removed through the vagina and the
vaginal vault was sutured laparoscopically. The operation was
completed by placing a drain on the pouch of Douglas.
We analyzed the characteristics and surgical outcomes of our
patients and compared them to previously reported results.
Results
Forty-nine patients who underwent TLmRH were included; of
these, 20 underwent TLmRH þ BSO, 18 underwent TLmRH þ
BSO þ PLA, and 11 underwent TLmRH þ BSO þ PLA þ PALA. The
characteristics of the patients and surgical results are summarized
in Table 1. The median age was 57 years (range, 39e77 years), the
median body mass index was 23.7 kg/m2 (range, 17.7e39.4 kg/m2),
and 24.5% of our patients had previous abdominal surgery. The
postoperative histological diagnosis of the majority of patients was
Grade 1 or 2 endometrioid carcinoma (43 cases, 88%). The staging of
the majority of patients was FIGO 1A (90%). The median operative
time was 204 minutes (range, 99e504 minutes), and the median
intraoperative blood loss was 150 mL (range, 0e680 mL). None of
the patients needed a blood transfusion, conversion to laparotomy,
or reoperation. The mean length of vaginal wall that was removed
with the uterus was 20.0 mm (range, 10.0e27.5 mm).
Intraoperative complications were observed in three patients
and included bladder, nerve, and ureter injury. The bladder injury
occurred during the TLmRH procedure and was managed lapa-
roscopically. The obturator nerve injury was observed during the
PLA procedure and was ﬁxed laparoscopically. The ureter injury
occurred during the PALA procedure and required the indwelling of
a urethral stent for 3 months after surgery. Postoperative compli-
cations were seen in nine patients (Table 1).
We compared these results to previous reports1,8e13 that stud-
ied patients who underwent laparoscopic hysterectomy for endo-
metrial cancer (Table 2). We found that the operative time was
longer in our study (median, 204 minutes) than in others
(75e204 minutes). The hospital stay after surgery also tended to be
longer in our study (6 days) than in others (2e4 days). However,
blood loss (150 mL vs. 100e171 mL), the incidence of intraoperative
complications (6.1% vs. 0e10.8%), and the incidence of
Table 3
Comparison with the previous reports of TLmRH with or without pelvic lymphadenectomy.
Present study Terai et al14 Ditto et al15 (cervical cancer)
(n ¼ 38) (n ¼ 39) (n ¼ 60)
Age (y) 55.5 (39e73) 56.6 ± 10 46 (29e79)
BMI (kg/m2) 23.5 (17.7e39.4) 22.5 ± 5.5 24.3 ± 2.9
No. of nulliparous 9 (23.7%) 9 (23.1%) NR
Surgical procedure
TLmRH 20 (52.6%) 15 (38.5%) 0
TLmRHþPLA 18 (47.4%) 24 (61.5%) 60 (100%)
Operative time (min) 192.5 (99e274) 321.1 ± 65.9 215.9 ± 61.6
Estimated blood loss (mL) 114 (0e680) 42.9 ± 76.3 50 (50e500)
Length of cervical cuff (mm) 20.0 (10.0e27.5) 12.0 ± 4.1 NR
No. of dissected pelvic lymph nodes 28 (15e47) 32.5 25.4 ± 10.0
Postoperative Hb value (g/dL) 10.4 (8.4e11.8) 11.5 ± 1.1 NR
Postoperative CRP value (mg/dL) 1.290 (0.131e10.577) 3.77 ± 2.7 NR
Time to passage of ﬂatus (d) 1 (1e3) 1.6 ± 0.6 NR
Blood transfusion required 0 0 (autologous 1) 1 (2%)
Conversion of laparoscopy to laparotomy 0 0 NR
Data are expressed as median (range), median ± standard deviation, or mean ± standard deviation.
BMI ¼ body mass index; NR ¼ not reported; PLA ¼ pelvic lymphadenectomy; TLmRH ¼ total laparoscopic modiﬁed radical hysterectomy.
M. Kitagawa et al. / Gynecology and Minimally Invasive Therapy 6 (2017) 6e1110postoperative complications (18.4% vs. 6.8e37.5%) were almost
identical to other reports.1,8e13
We also compared our results to previous reports14,15 that
studied patients who received TLmRH with or without PLA for
endometrial cancer or cervical cancer (Table 3). We found that the
estimated blood loss tended to be greater in our study than in
others and the operative time was equivalent.
The patients were followed every 2e3 months for ﬁrst
1e2 years and every 4e6 months thereafter for 5 years with
bimanual examination, Papanicolaou smear of vaginal stump, ul-
trasonography, and serum CA125. Examination with CT scan is
occasionally adopted. The median follow-up was 673 days (range,
97e1639 days). During the follow-up period, one patient of stage
1A, G1 who underwent TLmRH þ BSO had peritoneal metastasis
4 months after the surgery. However, she obtained complete
remission with chemotherapy. As of the latest follow-up, all pa-
tients were doing well and showed no signs of recurrence.
Discussion
The present study revealed that TLmRH is a feasible and safe
procedure for the treatment of early stage endometrial cancer.
When we compared our results to those in previously reported
studies of patients treated with total laparoscopic hysterectomy
(TLH),1,8e13 we tended to need more operating time. However, this
is partly because our procedure also included the time needed to
make the cervical cuff prior to the laparoscopic surgery and the
time needed for the lymphadenectomies. The postoperative hos-
pital stay also tended to be longer in this study. Although no study
has compared the hospital stay length between Japan and Western
countries, operated patients seem to have tendency to stay in the
hospital longer in Japan compared to Western countries. For
instance, in the studies that compare laparotomic and laparoscopic
mRH, Terai et al14 reported that mean days of hospital stay were
14.6 ± 12.6 and 9.3 ± 2.5, respectively, in a Japanese hospital. By
contrast, Ditto et al15 reported that median hospital stays were
6 days (3e14 days) and 4 days (3e11 days), respectively, in an
Italian hospital. These differences may be the reason for the results,
which showed longer postoperative hospital stay in this study.
When we compared our cases to those previously treated with
TLmRH, the estimated blood loss tended to be greater. The reason
for this is uncertain; however, it does not seem to be remarkable.
Aside from these observations, our results are comparable with
previous studies.14,15 In this study, transfusion, conversion tolaparotomy, and reoperationwere not observed. This may be due to
improvements in technical equipment and the experience level of
the surgeons.
Laparoscopic surgery has been increasingly utilized for patients
with early stage endometrial cancer, consistent with the trend to-
ward less invasive surgery. There have beenmany reports regarding
laparoscopic surgery for early stage endometrial cancer. de la Orden
et al16 performed a systemic review of four randomized clinical
trials and concluded that the safety and efﬁcacy of laparoscopic
surgery are equivalent to those of open surgery in the treatment of
early stage endometrial cancer. They also reported that laparo-
scopic surgery appears to have certain advantages: more rapid re-
covery, less pain, less bleeding, and fewer complications. The
numbers of lymph nodes resected were equivalent. The duration of
surgery tended to be longer for laparoscopic surgery. Tozzi et al17
reported that no difference was found between laparoscopic and
open surgery in terms of overall, disease free, or cause-speciﬁc
survival among patients with FIGO stage I to III endometrial can-
cer. Walker et al8 compared laparotomy and laparoscopy for the
surgical staging of endometrial cancer. In their report, laparoscopic
surgery was associated with shorter hospital stays and fewer
moderate-to-severe postoperative adverse events. Associated with
this study, reports have also found that patients had a superior
quality of life in the ﬁrst 6 postoperative weeks,18 comprehensive
surgical staging can be performed with similar overall survival, and
relatively small differences were observed in recurrence rates19 in
the patients with endometrial cancer treated with laparoscopy,
compared with those treated with laparotomy.
TLH is the current standard procedure for removing the uterus
laparoscopically. However, a risk of this procedure is the failure to
accomplish the extrafascial procedure fully, resulting in a small part
of the uterine cervix remaining. Han et al20 compared laparotomic
mRH and extrafascial hysterectomy in the treatment of stage I
endometrial cancer and they could not see the statistical difference
in recurrence rate and 5-year disease-free survival between them.
However, they reported that further studies using larger sample
sizes were needed because the different recurrence rate and 5-year
disease-free survival that might show the superiority of mRH were
observed in their small number of study population. Signorelli
et al21 also compared laparotomic mRH and extrafascial hysterec-
tomy in the treatment of stage I endometrial cancer. They
concluded that mRH did not improve locoregional control and
survival compared to class I or extrafascial hysterectomy; however,
mRH allows optional vaginal and pelvic control of disease with a
M. Kitagawa et al. / Gynecology and Minimally Invasive Therapy 6 (2017) 6e11 11minimal increase in surgical morbidity in cases where an adequate
vaginal cuff transection is not feasible with class I hysterectomy.
Because TLmRH resects the uterus thoroughly with some length of
vaginal wall, it may be a preferred option compared to extrafascial
hysterectomy. For this reason, we adopted TLmRH for the treatment
of early stage endometrial cancer. In this study, we obtained a
median length of resected vaginal wall of 20 mm. The incidence of
vaginal recurrence has been reported to be 3.1% in patients treated
with total abdominal hysterectomy and BSO without vaginal
brachytherapy.22 TLmRH may help to reduce this rate, although
further studies are needed to demonstrate the advantage of TLmRH
over TLH.
In conclusion, TLmRH is safe and feasible for the treatment of
early stage endometrial cancer. This procedure can be an alterna-
tive to TLH, especially in cases where the uterus must be removed
completely.References
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